Since the hotspot mutations in TERT promoter had been well accepted to create de novo binding sites for GABPA/GABPB complex, most of previous studies aiming at targeting mutant TERT in human cancers were focused on targeting GABPA and/or GABPB directly or indirectly. This evidence concerns the gene GABPB1 and cancer.